Successful Treatment for Adult Precursor B-Cell Lymphoblastic Lymphoma Involving Central Nervous System Monitored by 18F-Fluorodeoxyglucose PET/CT Imaging

Shi, Xiang; Zhou, Weiyan; Xu, Mingxin; Tao, Hua; Guan, Yihui

doi:10.3389/fonc.2020.00334

Cited by 2 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment response was evaluated at three time points (TP): TP1 or TP2 (days 15 or 33 of remission induction) and TP3 (prior to consolidation). Minimal disseminated disease (MDD) levels were detected in BM samples using computed tomography (CT) or positron emission tomography computed tomography (PET-CT) screening as described in previous literature reports, and disease status was evaluated as partial remission (PR), complete remission (CR), progressive disease (PD) or refractory disease (RD) (12)(13)(14). All patients with advanced stage were regarded as the intermediate risk (IR) group at diagnosis; patients who presented with PD at TP1, PR at TP1 and CR at TP2 were considered as the high risk (HR) group; patients who did not achieve CR at TP3 were considered as having RD.…”

Section: Patients and Treatmentmentioning

confidence: 99%

Genomic signatures and prognosis of advanced stage Chinese pediatric T cell lymphoblastic lymphoma by whole exome sequencing

Liu,

Yu,

Wen

et al. 2023

Front. Pediatr.

View full text Add to dashboard Cite

ObjectiveTo investigate the genomic signatures and prognosis of advanced-stage T cell lymphoblastic lymphoma (T-LBL) and to examine the relationship between T-LBL and T cell acute lymphoblastic leukemia (T-ALL).Methods35 Chinese T-LBL children with stage III or IV disease were recruited for this study. They were treated with combination chemotherapy and whole exome sequencing. The relationship of the clinical features, prognosis and specific gene mutations was researched. Gene chips of T-LBL and T-ALL were downloaded from a database, and differential gene expression was analyzed.ResultsGermline causal gene mutations (CARS or MAP2K2) were detected in 2 patients; 3.06 ± 2.21 somatic causal gene mutations were identified in the 35 patients, and somatic mutations were observed in the NOTCH1, FBXW7, PHF6 and JAK3 genes. NOTCH1 mutations were signiﬁcantly associated with FBXW7 mutations, and the age at diagnosis of patients with NOTCH1-FBXW7 mutations was less than that of patients without such mutations (P < 0.05). 32 patients achieved complete remission (CR), and 14 and 18 patients were classified into the intermediate risk (IR) group and high risk (HR) group. During a median follow-up of 44 months, 3 patients relapsed. Three-year prospective event free survival (pEFS) was 82.286%, and no significant differences of pEFS were found for different sexes, ages, or statuses of NOTCH1-FBXW7 mutations, (P > 0.05); however, the mean survival time of the IR group was longer than that of the HR group (P < 0.05). Differential expression of genes in the T-LBL and/or T-ALL datasets was analyzed using the R package limma, and 1/3 of the differentially expressed genes were found in both the T-ALL and T-LBL datasets. High expression of PI3K-Akt signal pathway genes and the USP34 gene was found in the T-LBL dataset.ConclusionAlthough T-ALL and T-LBL both originate from precursor T-cells and are considered different manifestations of the same disease and the outcome of T-LBL is favorable when using T-ALL-based chemotherapy, there are differences in the gene distribution between T-LBL and T-ALL. It seems that the PI3K-Akt signaling pathway and the USP34 gene play important roles in T-LBL, but medicines targeting the USP34 gene or the PI3K-Akt pathway may be invalid.

show abstract

Section: Patients and Treatmentmentioning

confidence: 99%